Journal of Clinical Endocrinology & Metabolism, Vol 78, 1268-1270, Copyright © 1994 by Endocrine Society

ARTICLES

Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients

M Pecherstorfer, T Schilling, E Blind, I Zimmer-Roth, G Baumgartner, R Ziegler and F Raue
Department of Oncology, Lainz Hospital, Vienna, Austria.

We determined the effect of raised serum levels of midregional (53-84) parathyroid hormone-related protein (PTHrP) on life expectancy in 59 cancer patients with first presentation of hypercalcemia. The patients were stratified according to the serum PTHrP levels measured on day 0 after fluid repletion prior to bisphosphonate therapy. Twenty-nine patients were assigned to group N (PTHrP < or = 21 pmol/L) and 30 to group E (PTHrP > 21 pmol/L). Breast cancers were more common in group N, squamous cell cancers predominated in group E (p < 0.02). More patients with normal PTHrP had skeletal metastases, whereas group E was characterized by a higher incidence of prognostically unfavorable visceral involvement (p < 0.001). Bisphosphonates (pamidronate or BM.210955) were administered on day 0. Within one week, normocalcemia (serum calcium < or = 2.6 mmol/L) was restored in 96% of patients in group N, compared to 70% of patients in group E (p < 0.01). On day 12, 7 patients with elevated PTHrP were still hypercalcemic. Although a comparable number of patients in the two groups received cytostatic treatment after day 12, objective tumor responses were seen only in group N (n = 6; p < 0.05). Calculated from the first occurrence of hypercalcemia, the median survival was 66 days in group N and 33 days in group E (log-rank test: p = 0.0456; Wilcoxon-Breslow test: p = 0.0475). We conclude that in hypercalcemia of malignancy raised serum levels of PTHrP indicate a reduced hypocalcemic response to bisphosphonates, a more advanced tumor state and, therefore, an extremely poor prognosis.

This article has been cited by other articles:

				N Walji, A K Chan, and D R Peake Common acute oncological emergencies: diagnosis, investigation and management Postgrad. Med. J., August 1, 2008; 84(994): 418 - 427. [Abstract] [Full Text] [PDF]

				S. Morony, K. Warmington, S. Adamu, F. Asuncion, Z. Geng, M. Grisanti, H. L. Tan, C. Capparelli, C. Starnes, B. Weimann, et al. The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy Endocrinology, August 1, 2005; 146(8): 3235 - 3243. [Abstract] [Full Text] [PDF]

				K. Kawada, H. Minami, K. Okabe, T. Watanabe, K. Inoue, M. Sawamura, Y. Yagi, T. Sasaki, and S. Takashima A Multicenter and Open Label Clinical Trial of Zoledronic Acid 4 mg in Patients with Hypercalcemia of Malignancy Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 28 - 33. [Abstract] [Full Text] [PDF]

				R. H. Hastings, F. Araiza, D. W. Burton, M. Bedley, and L. J. Deftos Parathyroid hormone-related protein regulates apoptosis in lung cancer cells through protein kinase A Am J Physiol Cell Physiol, December 1, 2004; 287(6): C1616 - C1622. [Abstract] [Full Text] [PDF]

				R. H. Hastings, F. Araiza, D. W. Burton, L. Zhang, M. Bedley, and L. J. Deftos Parathyroid hormone-related protein ameliorates death receptor-mediated apoptosis in lung cancer cells Am J Physiol Cell Physiol, December 1, 2003; 285(6): C1429 - C1436. [Abstract] [Full Text] [PDF]

				R. Rizzoli, D. Thiebaud, N. Bundred, M. Pecherstorfer, Z. Herrmann, H. J. Huss, F. Ruckert, C. Manegold, M. Tubiana-Hulin, E. U. Steinhauer, et al. Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3545 - 3550. [Abstract] [Full Text] [PDF]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]